Endocannabinoid Signaling in Autism Bhismadev Chakrabarti, Antonio Persico, Natalia Battista, Mauro Maccarrone Neurotherapeutics, 2015, Volume 12, Issue 4, 837-847. DOI 10.1007/s13311-015-0371-9 Abstract Autism spectrum disorder (ASD) is a complex behavioral condition with onset during early childhood and a lifelong course in the vast majority of cases. To date, no behavioral, genetic, brain imaging, or electrophysiological test can specifically validate a clinical diagnosis of ASD. However, these medical procedures are often implemented in order to screen for syndromic forms of the disorder (i.e., autism comorbid with known medical conditions). In the last 25 years a good deal of information has been accumulated on the main components of [...]
Lire la suiteAutism Spectrum Disorder and Cannabidiol : Have We Seen This Movie Before? Carlos A. Salgado, and Daniel Castellanos, Glob Pediatr Health. 2018; 5: 2333794X18815412 doi: 10.1177/2333794X18815412 Received July 5, 2018. Received revised October 9, 2018. Accepted for publication October 23, 2018. Recently, the use of marijuana and cannabidiol (CBD) in children with autism spectrum disorder (ASD) has received increasing attention in the media with articles sensationally titled “Marijuana may be a miracle treatment for children with autism.” An absence of empirical data appears to have resulted in a growing body of anecdotal evidence espousing the benefits of CBD for children with ASD. Some reports describe the [...]
Lire la suiteCannabinoids for Behavioral Problems in Children With ASD (CBA) ClinicalTrials.gov Identifier : NCT02956226 Recruitment Status : Completed First Posted : November 7, 2016 Last Update Posted : December 27, 2018 https://clinicaltrials.gov/ct2/show/NCT02956226?term=cannabidiol&cond=Autism+Spectrum+Disorder Sponsor : Shaare Zedek Medical Center Information provided by (Responsible Party) : Dr. Adi Aran, Shaare Zedek Medical Center Study Description Brief Summary : This study aims to assess the safety, tolerability and efficacy of cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio, BOL Pharma, Israel] for behavioral problems in children and youth with ASD. Condition or disease Intervention/treatment Phase Autistic Disorder Drug: Cannabinoids - 99% pure cannabinoids mixDrug: PlaceboDrug: Cannabinoids - whole plant extract Study Design Study [...]
Lire la suiteCannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) ClinicalTrials.gov Identifier : NCT03202303 Recruitment Status : Not yet recruiting First Posted : June 28, 2017 Last Update Posted : April 2, 2019 https://clinicaltrials.gov/ct2/show/NCT03202303?term=cannabinoids&cond=Autism+Spectrum+Disorder&rank=2 Sponsor : Eric Hollander Collaborators : United States Department of Defense, GW Pharmaceuticals Information provided by (Responsible Party) : Eric Hollander, Montefiore Medical Center, USA Study Design Study Type : Interventional (Clinical Trial) Estimated Enrollment : 100 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Phase 2, 12-week double-blind, randomized, placebo-controlled trial Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Masking Description: Double-Blind Primary Purpose: Treatment Official Title: Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) Estimated Study Start Date : June 2019 Estimated [...]
Lire la suiteA cannabis reader : global issues and local experiences. Perspectives on cannabis controversies, treatment and regulation in Europe EMCDDA MONOGRAPHS, 8 Volume 1 Editors : Sharon Rödner Sznitman, Börje Olsson, Robin Room European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 2008 — 392 pp. Contents Introduction Foreword : Wolfgang Götz Overview of Volume 1 : Sharon Rödner Sznitman and Börje Olsson Part I : Cannabis in the past Chapter 1 : Cannabis as medicine in Europe in the 19th century : Manfred Fankhauser Chapter 2 : The re-emergence of the therapeutic use of cannabis products : recent developments and future prospects : John Witton Chapter 3 : The pharmacology of cannabis: [...]
Lire la suiteHashish revival in Morocco Pierre-Arnaud Chouvy, Kenza Afsahi International Journal of Drug Policy, 2014, Vol. 25, Issue 3, 416-423. http://dx.doi.org/10.1016/j.drugpo.2014.01.001 © 2014 Elsevier B.V. All rights reserved. Ab s t r a c t Background : In less than a decade, Morocco reportedly saw cannabis cultivation decrease by 65%, and hashish production is widely believed to have followed the same trend. Yet large anomalies exist between the alleged fall of hashish production in Morocco and international seizure data. While no explanation for such a discrepancy existed, the main hypothesis was that cannabis cultivation and hashish production had not declined to the extent suggested by the available [...]
Lire la suite“Should I Buy or Should I Grow?” How drug policy institutions and drug market transaction costs shape the decision to self-supply with cannabis in the Netherlands and the Czech Republic Vendula Belackovaa, Nicole Maalsté, Tomas Zabranskya, Jean Paul Grund International Journal of Drug Policy, 2015, 26, 293-310 © 2015 Elsevier B.V. All rights reserved. A b s t r a c t Background : This paper uses the framework of institutional economics to assess the impact of formal and informal institutions that influence the transaction costs on the cannabis market, and users’ decisions to self-supply in the Czech Republic and the Netherlands, two countries with [...]
Lire la suiteRhumatismes : l’efficacité du cannabis sur la douleur reste à démontrer Stéphanie Lavaud Medscape, 7 juillet 2014 https://francais.medscape.com/voirarticle/3600758 Si l’efficacité des cannabinoïdes pour le traitement de certaines douleurs chroniques, comme celles liées au cancer ou aux maladies neuropathiques, a été alléguée, voire démontrée, qu’en est-il des pathologies rhumatologiques ? Dans une session consacrée au sujet du congrès de l’ European League Against Rheumatism (EULAR 2014), le Dr Mary-Ann Fitzcharles, rhumatologue et professeur de médecine à l’Université de McGill, a été claire : il n’existe pas d’étude formelle ni sur le court terme ni sur le long terme montrant que fumer de l’ « herbe » soulage [...]
Lire la suiteDouleurs rhumatismales : les cannabinoïdes peuvent-ils les soulager ? Aude Lecrubier Medscape, 28 décembre 2016 https://francais.medscape.com/voirarticle/3602900 Alors que de nombreux patients atteints de pathologies rhumatologiques souffrent de douleurs chroniques et que le cannabis à usage thérapeutique semble connaître un véritable essor, notamment en Amérique du Nord, une méta-analyse du Dr Mary-Ann Fitzcharles (Rhumatologue, Université de McGill, Canada) et coll. rapporte des résultats décevants (voir aussi notre article). En l’état, les données de la littérature suggèrent que les cannabinoïdes ne présentent pas d’intérêt pour soulager les douleurs rhumatismales [1]. « Ce que montre cette méta-analyse, c’est que l’effet antalgique est très modeste. En outre, il y a une [...]
Lire la suitehttps://www.respadd.org/24es-rencontres-du-respadd-usages-cliniques-des-cannabinoides/
Lire la suite